OptimizeRx Corp: management transactions · United States · SEC (Form 4)

About OptimizeRx Corp

OptimizeRx Corp. (Nasdaq: OPRX) is a U.S.-listed healthcare technology company traded on the NASDAQ Capital Market in the United States. For French, Belgian and Swiss investors, the company sits at the intersection of healthcare, software, and pharmaceutical marketing. Headquartered in Waltham, Massachusetts, OptimizeRx was founded in 2006. Its business is centered on a technology platform that helps life sciences companies better reach and engage healthcare professionals (HCPs) and patients in a market shaped by regulation, data privacy requirements, and workflow integration. ([investors.optimizerx.com](https://investors.optimizerx.com/investor-relations)) OptimizeRx originally built solutions around coupons, co-pay assistance, and patient support delivered through electronic health record and e-prescribing workflows. Over time, the company evolved into a broader digital health and commercial engagement platform, combining software, data, analytics, and targeted activation capabilities. The acquisition of Medicx Health expanded the company’s consumer-focused omnichannel reach and strengthened its ability to connect HCP and direct-to-consumer strategies within a single privacy-safe framework. ([optimizerx.com](https://www.optimizerx.com/about-us?utm_source=openai)) Today, its main business lines include point-of-care solutions, in-workflow clinical messaging, audience activation, patient targeting, and privacy-safe omnichannel marketing. OptimizeRx emphasizes an AI-enabled approach designed to deliver timely, relevant messages at the moment of care and to improve treatment access and decision-making. From a competitive standpoint, the company differentiates itself through its embedded presence in EHR/eRx channels, its ability to connect brands with both providers and consumers, and its positioning as a commercial technology partner to pharmaceutical and broader life sciences budgets. ([investors.optimizerx.com](https://investors.optimizerx.com/investor-relations)) Geographically, OptimizeRx is primarily focused on the United States, which is the natural market for its point-of-care and pharmaceutical engagement model given the structure of U.S. prescribing, healthcare workflows, and healthcare advertising rules. The company serves a national base of pharmaceutical and life sciences clients from its Waltham, Massachusetts headquarters. Recent communications also point to continued network expansion, strategic renewals, and deeper ecosystem partnerships. ([investors.optimizerx.com](https://investors.optimizerx.com/static-files/261cfad9-d91a-4bde-a9da-dfd3276f0075)) Recent developments have been constructive. In second-quarter 2025 results, OptimizeRx reported 55% revenue growth to $29.2 million, higher gross profit, a return to GAAP profitability, and increased full-year 2025 guidance. Management also highlighted stronger contracted revenue, continued free-cash-flow generation, and accelerated debt repayment. For investors, the key takeaway is an improving profile of profitable growth, although the company remains exposed to customer concentration and the spending patterns of pharmaceutical marketers. ([investors.optimizerx.com](https://investors.optimizerx.com/static-files/261cfad9-d91a-4bde-a9da-dfd3276f0075))